John M. Climaco - 12 Nov 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)

Reporting relationship: Director
Issuer ticker: MBRX
Reported as of: 12 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Nov 2025, 16:05:51 UTC
Prior SEC filing: 06 Nov 2024
Next SEC filing: 19 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Foster by Power of Attorney

Key filing fact

John M. Climaco filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 14 Nov 2025.

Key facts

This page summarizes John M. Climaco's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Nov 2025, 16:05.

Change

Previous filing in this sequence was filed on 06 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001546797 Primary reporting owner

Climaco John M

Relationship: Director
Address: C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON
Signature: /s/ Jonathan Foster by Power of Attorney
Signature date: 14 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBRX transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +150,000
Change %: +989%
Price
Shares after: 165,169
Date: 12 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.4900
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options set forth in this table vest on November 12, 2026, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

Footnote F2

The options were issued in connection with the reporting person's Board of Director service to the Company.